Thykamine

Drug Profile

Thykamine

Alternative Names: PCT-233; PUR-0110; Thykamine™

Latest Information Update: 04 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PurGenesis Technologies
  • Developer Devonian
  • Class Anti-inflammatories; Skin disorder therapies
  • Mechanism of Action Antioxidants; Cytokine inhibitors; Interleukin 10 modulators; Reactive oxygen species inhibitors; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Preclinical Psoriasis

Most Recent Events

  • 04 Jul 2017 Updated pharmacodynamics, efficacy and safety data from a phase IIa trial in Ulcerative colitis reported by Devonian (3255712; 3254897)
  • 30 Jun 2017 Devonian intends to request a meeting with the US FDA by the end of 2017 for the planned phase IIb trial in Ulcerative colitis (Rectal, Enema)
  • 22 Jun 2017 Devonian plans a phase IIa trial for Atopic dermatitis in Canada (Topical, Cream)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top